The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma (msn.com)
- Forums
- ASX - By Stock
- ALA
- FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
ALA
arovella therapeutics limited
Add to My Watchlist
18.8%
!
9.5¢

FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
9.5¢ |
Change
0.015(18.8%) |
Mkt cap ! $113.6M |
Open | High | Low | Value | Volume |
8.1¢ | 9.5¢ | 8.1¢ | $182.2K | 2.104M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 141934 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 141934 | 0.095 |
2 | 30825 | 0.090 |
3 | 88126 | 0.089 |
4 | 171218 | 0.088 |
2 | 46888 | 0.087 |
Price($) | Vol. | No. |
---|---|---|
0.097 | 100000 | 1 |
0.098 | 250000 | 1 |
0.099 | 158000 | 2 |
0.100 | 1090473 | 4 |
0.110 | 525500 | 5 |
Last trade - 16.10pm 16/09/2025 (20 minute delay) ? |
Featured News
ALA (ASX) Chart |